Relebactam sodium
Based on 30 publication(s) in Google Scholar
Relebactam sodium (MK-7655 sodium) is a potent and selective β-lactamase inhibitor with the activity of delaying the development of bacterial resistance to antibiotics. Relebactam sodium can bind to a variety of β-lactamases, thereby improving the efficacy of β-lactam antibiotics. Relebactam sodium shows good application potential in inhibiting complicated bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 1502858-91-4
- Formula: C12H19N4NaO6S
- Molecular Weight:370.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Relebactam sodium
More- Int J Antimicrob Agents. 2025 Jun 4:107550. [Abstract]
- Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]
- Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]
- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0126725. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2024 Aug 19:e0069324. [Abstract]
- Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0034623. [Abstract]
- Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. [Abstract]
- Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]
- Antimicrob Agents Chemother. 2020 Nov 17;64(12):e00297-20. [Abstract]
- Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02255-19. [Abstract]
- Sci Rep. 2022 Oct 7;12(1):16814. [Abstract]
- ACS Infect Dis. 2024 May 10;10(5):1624-1643. [Abstract]
- Microbiol Spectr. 2023 Dec 12;11(6):e0304723. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0069223. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0303822. [Abstract]
- ACS Infect Dis. 2021 Apr 9;7(4):826-837. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- J Glob Antimicrob Resist. 2022 Dec:31:1-9. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):571-585. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):277-284. [Abstract]
- Infect Drug Resist. 2020 Aug 18;13:2883-2890. [Abstract]
- Diagn Microbiol Infect Dis. 2024 Dec;110(4):116474. [Abstract]
- bioRxiv. 2025 January 21.
- Res Sq. 2024 Nov 26.
- bioRxiv. 2021 Mar 13.
-
Microbiological Assay
-
Bio/Physico-chemical Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
All Beta-lactamase Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 1502858-91-4
-
Molecular Weight 370.36
-
Formula C12H19N4NaO6S
-
SMILES
O=S(ON1[C@]2([H])CC[C@@H](C(NC3CCNCC3)=O)[N@@](C2)C1=O)(O[Na])=O
-
Synonyms
MK-7655 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Int J Antimicrob Agents
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022. [Abstract]2025 Jun 4:107550. PMID: 40480535 -
Int J Antimicrob Agents
MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]2024 May 14:107206. PMID: 38754526
Relebactam sodium purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]
The MultiRapid ATB NP test. Column D shows the solution with imipenem–relebactam (IPR, 12/4 mg/L);. Reference strain Escherichia coli ATCC 25922 was inoculated in wells A1–F1; Positive control resistant to all the antibiotics was inoculated in wells A2–F2; First tested strain (resistant to CZA, MEV, and IPR) was inoculated in wells A3–F3; Second tested strain (resistant to CZA and FDC) was inoculated in wells A4–F4; and NaCl 0.85% was inoculated in wells A5–F5. Bacterial growth is shown by a colour change of the medium from red to yellow.
-
Int J Antimicrob Agents
In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. [Abstract]2022 Nov-Dec;60(5-6):106669. PMID: 36064079
Relebactam sodium purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]
The MICs of seven β-lactams with relebactam 8 mg/L against M. abscessus.
Relebactam sodium purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]
The MICs of seven β-lactams with relebactam 8 mg/L against M. massiliense.
-
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279
Relebactam sodium purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
Twenty-four-hour time–kill curves of aztreonam (ATM) and relebactam (REL), alone and in combination, on: C. amalonaticus N18; K. pneumoniae KL 12 SG; K. pneumoniae LC954/14.
-
Antimicrob Agents Chemother
Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]2026 Jun 3;70(6):e0126725. PMID: 42053451 -
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. [Abstract]2024 Aug 19:e0069324. PMID: 39158279 -
Antimicrob Agents Chemother
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. [Abstract]2023 Dec 14;67(12):e0034623. PMID: 37971240 -
Antimicrob Agents Chemother
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2023 Jul 18;67(7):e0033923. PMID: 37255469 -
Antimicrob Agents Chemother
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. [Abstract]2023 Jun 15;67(6):e0160322. PMID: 37199612
Relebactam sodium purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]
Difference between whole cells and isolated PBPs fraction unbound. P. aeruginosa PAO1 cultures (whole cells) and PBP-containing membrane preparations (isolated) were incubated for 15, 30, and 60 min in the presence of relebactam (REL), and afterwards isolated PBPs labeled with 25 μM Boc-FL.
-
Antimicrob Agents Chemother
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. [Abstract]2020 Nov 17;64(12):e00297-20. PMID: 32928733 -
Antimicrob Agents Chemother
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens. [Abstract]2020 Mar 24;64(4):e02255-19. PMID: 31932381 -
Sci Rep
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. [Abstract]2022 Oct 7;12(1):16814. PMID: 36207358 -
ACS Infect Dis
3- O-Substituted Quercetin: an Antibiotic-Potentiating Agent against Multidrug-Resistant Gram-Negative Enterobacteriaceae through Simultaneous Inhibition of Efflux Pump and Broad-Spectrum Carbapenemases. [Abstract]2024 May 10;10(5):1624-1643. PMID: 38652574 -
Microbiol Spectr
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients. [Abstract]2023 Dec 12;11(6):e0304723. PMID: 37982634 -
Microbiol Spectr
Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]2023 Jun 15;11(3):e0069223. PMID: 37093051 -
Microbiol Spectr
PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. [Abstract]2023 Feb 14;11(1):e0303822. PMID: 36475840 -
ACS Infect Dis
Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. [Abstract]2021 Apr 9;7(4):826-837. PMID: 33723985 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
J Glob Antimicrob Resist
In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. [Abstract]2022 Dec:31:1-9. PMID: 35820591 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]2025 Mar;44(3):571-585. PMID: 39704920 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]2025 Feb;44(2):277-284. PMID: 39589655 -
Infect Drug Resist
Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem. [Abstract]2020 Aug 18;13:2883-2890. PMID: 32903882 -
Diagn Microbiol Infect Dis
Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa. [Abstract]2024 Dec;110(4):116474. PMID: 39191152 -
-
-
Purity & Documentation
References
[1]. Lapuebla A, et al. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. [Content Brief]
[2]. Imipenem monohydrate/cilastatin sodium/relebactam monohydrate, pretomanid, and elexacaftor/tezacaftor/ivacaftor [Content Brief]
[3]. Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)